European Commission Approves Endoceutics’ Drug IntrarosaTM for the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women
The European Commission has adopted the following on 8 January 2018: Adoption of Commission Implementing Decision granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Intrarosa - Prasterone," a medicinal product for human... - January 15, 2018
The European Medicines Agency Accepts Marketing Authorisation Application for Intrarosa for the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women
Endoceutics Inc., a private Quebec City based biopharma company, today announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product IntrarosaTM, intended for the treatment of... - November 13, 2017
Now More Hope for Menopausal Women Experiencing the Physical and Emotional Impact of Painful Sex and Vaginal Dryness
New clinical data released on Prasterone (DHEA) Vaginal Ovules' positive effect on moderate to severe dyspareunia (Painful sex due to menopause) and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. - January 06, 2016